BOEHRINGER-INGELHEIM
7.7.2020 14:02:14 CEST | Business Wire | Press release
Boehringer Ingelheim and Numab Therapeutics (Numab) today announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic atrophy (GA), a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. The collaboration brings together Boehringer Ingelheim’s leading expertise in the research and development of life changing breakthrough therapies with Numab’s multi-specific antibody platform.
Lung and GI cancers and retinal diseases are key focus areas of Boehringer Ingelheim’s research and development program. In oncology the company has built a broad and diverse pipeline, combining cancer immunology and cancer cell directed approaches. The novel T-cell engager to be developed with Numab adds to Boehringer Ingelheim’s growing cancer immunology portfolio and supports the strategy to take cancer on by targeting ‘cold’ tumors with synergistic combination approaches. In retinal diseases Boehringer Ingelheim is pursuing a holistic approach leveraging existing expertise in oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases. The new GA program with Numab further broadens the company’s comprehensive portfolio of next generation retinal therapy approaches in various stages of development up to Phase 2 in macular degeneration and diabetic retinal diseases.
“We are thrilled to work with the excellent team at Numab to advance our portfolio assets. Numab’s technology platform fits well with our internal antibody discovery and engineering capabilities and will enhance our efforts to deliver transformative antibody-based therapeutics to patients,” said Paige Mahaney, SVP and US Discovery Research Site Head at Boehringer Ingelheim.
“We are looking forward to working with Boehringer Ingelheim, a global leader in pharmaceutical R&D with profound expertise across a broad spectrum of therapeutic areas, further validating our technology platform. This addition to our growing roster of partnerships represents another key milestone in our business development efforts,” commented Dr. Oliver Middendorp, Chief Business Officer of Numab Therapeutics. “The upfront payment and near-term milestones attached to this alliance will further strengthen Numab’s ability to accelerate the development of key proprietary assets.”
Under the terms of the alliance, the partners will work together to discover one novel multi-specific antibody drug candidate in each area. Boehringer Ingelheim receives from Numab an exclusive worldwide license to develop and commercialize the resulting candidates in exchange for upfront and milestone payments, as well as tiered royalties on net sales of all products resulting from the alliance.
With today’s announcement, Numab has been able to secure seven ongoing relationships with leading pharmaceutical companies including 3SBio / Sunshine Guojian, Boehringer Ingelheim, Eisai Co., Ltd., CStone Pharmaceuticals, Ono Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., and Tillotts Pharma AG.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/numab
View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005453/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Delhaize BeLux Achieves Up to 90% Forecast Accuracy Using SymphonyAI's AI-Driven Replenishment Platform12.8.2026 09:05:00 CEST | Press release
Ahold Delhaize grocery retailer deploys SymphonyAI across 600 stores and five distribution centers, cutting shrink and improving forecast accuracy by up to 10 percentage points When a grocery retailer operates under a pure B2B affiliate model, it cannot push excess inventory to its store partners — which means forecasting has to be right, or the distribution center absorbs the cost. SymphonyAI, a global leader in Vertical AI, today announced that Delhaize, part of the Ahold Delhaize Group, has deployed SymphonyAI's Demand Forecasting and Replenishment solutions across its 600-store affiliated network and five distribution centers in Belgium, replacing reactive, manually intensive ordering processes with an AI-driven, exception-based workflow. The Delhaize Le Lion / De Leeuw network has no less than 1113 stores in Belgium and Luxembourg. The store network consists of different formulas: Delhaize, Proxy, Shop&Go and louis delhaize. Customers can also shop online via www.delhaize.be, and
Align Technology Prevails in China Patent Infringement Action Against Angelalign12.8.2026 02:47:00 CEST | Press release
Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, today announced that the Jinan Intermediate People's Court in China issued a judgment in favor of Align in a patent infringement action against Angelalign Technology's operating subsidiaries in China ("Angel") (Hong Kong Stock Exchange: 6699.HK). In September 2025, Align filed a patent infringement action against Angel in the Jinan Intermediate People's Court, asserting Align’s patent related to extraction-gap-closure technology (CN113693748B). On August 10, 2026, the Jinan Intermediate People's Court issued a first-instance judgment finding that Angel's use of its MasterForce biomechanical simulation system and ATreat digital orthodontic treatment design system to generate A7 and A7 Speed premolar extraction treatment solutions infringes Align's patent rights. The court further found that the related aligner products m
Entrepreneurs Invited to Apply for 2027 SPIE Startup Challenge11.8.2026 20:40:00 CEST | Press release
The competition will bring seven teams head-to-head in pursuit of $10,000 first prize Entrepreneurs around the world are invited to apply for a chance to pitch their optics or photonics technologies or products to a panel of expert judges at the 17th annual SPIE Startup Challenge. SPIE, the international society of optics and photonics, holds the competition at Photonics West every January, with multiple teams walking away with cash prizes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811090450/en/ Coalesenz won first prize for their hand-held, point-of-care coagulation analyzer at the SPIE Startup Challenge at Photonics West in January 2026. More than a simple pitch competition, the SPIE Startup Challenge is an entry point into the community of high-tech business development of new products in healthcare and deep tech, with an audience of experienced photonics innovators and investors. Cash prizes of $10,000, $5,000, a
The Aga Khan Museum Welcomes Prince Aly Muhammad Aga Khan and Saira Bhojani to its Board of Directors11.8.2026 17:30:00 CEST | Press release
The Aga Khan Museum is pleased to announce the appointment of Prince Aly Muhammad Aga Khan and Saira Bhojani to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811597825/en/ Prince Aly Muhammad Aga Khan, board member, Aga Khan Museum Prince Aly Muhammad Aga Khan joins the Board with a deep commitment to arts and culture. He brings an international outlook shaped by working with the Aga Khan Foundation and Aga Khan Music Programme. Committed to advancing pluralism and cultural dialogue, Prince Aly brings a fresh perspective that will help guide the Museum as it continues to evolve, engage new audiences, and expand its impact both in Canada and internationally. Prince Aly is the son of His Late Highness Prince Karim Aga Khan IV and brother of His Highness Prince Rahim Aga Khan V. Joining him on the Board is Saira Bhojani, Partner at Torys LLP and one of Canada's leading tax lawyers. Ms. Bhojani is wid
Mouser Explores the Future of Quantum Computing and Its Potential to Transform Engineering11.8.2026 16:48:00 CEST | Press release
Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, today announced the latest installment of its Empowering Innovation Together (EIT) technology series, A Quantum Leap in Computer Processing. This installment explores the emerging field of quantum computing and examines how the principles of quantum mechanics could unlock new computational capabilities for solving problems that remain difficult for conventional computing architectures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811222432/en/ Explore how quantum computing could help engineers address problems too complex for traditional systems. Unlike traditional computers, quantum computers leverage quantum-mechanical phenomena, such as superposition, entanglement, and interference, to perform calculations in fundamentally different ways. While today's quantum systems still face challe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom